Several mutations are required for cancer development, and genome sequencing has revealed that many cancers, including breast cancer, have somatic mutation spectra dominated by C-to-T transitions [1] [2] [3] [4] [5] [6] [7] [8] [9] . Most of these mutations occur at hydrolytically disfavoured 10 non-methylated cytosines throughout the genome, and are sometimes clustered 8 . Here we show that the DNA cytosine deaminase APOBEC3B is a probable source of these mutations. APOBEC3B messenger RNA is upregulated in most primary breast tumours and breast cancer cell lines. Tumours that express high levels of APOBEC3B have twice as many mutations as those that express low levels and are more likely to have mutations in TP53. Endogenous APOBEC3B protein is predominantly nuclear and the only detectable source of DNA C-to-U editing activity in breast cancer cell-line extracts. Knockdown experiments show that endogenous APOBEC3B correlates with increased levels of genomic uracil, increased mutation frequencies, and C-to-T transitions. Furthermore, induced APOBEC3B overexpression causes cell cycle deviations, cell death, DNA fragmentation, c-H2AX accumulation and C-to-T mutations. Our data suggest a model in which APOBEC3B-catalysed deamination provides a chronic source of DNA damage in breast cancers that could select TP53 inactivation and explain how some tumours evolve rapidly and manifest heterogeneity.
Several mutations are required for cancer development, and genome sequencing has revealed that many cancers, including breast cancer, have somatic mutation spectra dominated by C-to-T transitions [1] [2] [3] [4] [5] [6] [7] [8] [9] . Most of these mutations occur at hydrolytically disfavoured 10 non-methylated cytosines throughout the genome, and are sometimes clustered 8 . Here we show that the DNA cytosine deaminase APOBEC3B is a probable source of these mutations. APOBEC3B messenger RNA is upregulated in most primary breast tumours and breast cancer cell lines. Tumours that express high levels of APOBEC3B have twice as many mutations as those that express low levels and are more likely to have mutations in TP53. Endogenous APOBEC3B protein is predominantly nuclear and the only detectable source of DNA C-to-U editing activity in breast cancer cell-line extracts. Knockdown experiments show that endogenous APOBEC3B correlates with increased levels of genomic uracil, increased mutation frequencies, and C-to-T transitions. Furthermore, induced APOBEC3B overexpression causes cell cycle deviations, cell death, DNA fragmentation, c-H2AX accumulation and C-to-T mutations. Our data suggest a model in which APOBEC3B-catalysed deamination provides a chronic source of DNA damage in breast cancers that could select TP53 inactivation and explain how some tumours evolve rapidly and manifest heterogeneity.
Most humans encode a total of 11 polynucleotide cytosine deaminase family members that could contribute to mutation in cancer-APOBEC1, activation-induced deaminase (AID), APOBEC2, APOBEC3 proteins (known as A3A, A3B, A3C, A3D, A3F, A3G and A3H), and APOBEC4. APOBEC2 and APOBEC4 have not shown activity. APOBEC1 and AID are expressed tissue specifically and implicated in cancers of those tissues, hepatocytes and B cells, respectively 11, 12 . We therefore proposed that one or more of the seven APOBEC3 proteins may be responsible for the C-to-T mutations in other human cancers. This possibility is consistent with hybridization 13 and expression studies 14 ( Supplementary Fig. 1 ).
To identify the contributing APOBEC3 protein, we quantified mRNA levels for each of the 11 family members in breast cancer cell lines ( Supplementary Fig. 2) . Surprisingly, only APOBEC3B mRNA trended towards upregulation. This analysis was expanded to include a total of 38 independent breast cancer cell lines. APOBEC3B was upregulated by $3 s.d. relative to controls in 28 out of 38 lines, with levels exceeding tenfold in 12 out of 38 lines (Fig. 1a and Supplementary Table 1 ). Of the representative cell lines used, MDA-MB-453, MDA-MB-468 and HCC1569 showed 20-, 21-and 61-fold upregulation, respectively. These results correlate with cell-line microarray data ( Supplementary Fig. 3 , Supplementary Tables 2-9 and Supplementary Discussion). APOBEC3B upregulation is probably due to an upstream signal transduction event because it is not a frequent site of rearrangement or copy number variation (http:// dbCRID.biolead.org), and sequencing failed to reveal promoter-activating mutations or CpG islands indicative of epigenetic regulation ( Supplementary Fig. 4 ).
Epitope-tagged APOBEC3B (A3B) localizes to the nucleus of several transfected cell types 15 . To determine whether this is also a property of breast cancer lines, a construct encoding A3B fused to enhanced green fluorescent protein (A3B-eGFP) was transfected into MDA-MB-453, Immortalized cell lines   HCC38  AU-565  SK-BR-3  hTERT-HMEC  MCF-10A  MCF-10F  MCF-12A  HCC-70  HCC-1500  DU-4475  BT-549  Hs578Bst  BT-483  184B5  HCC1395  HCC2218  UACC-812  CAMA-1  ZR-75-30  T47D  HCC1419  HCC1937  MCF-7  HCC1954  MDA-MB-175-VII  MDA-MB-436  BT-20  MDA-MB-361  HCC1187  ZR-75-1  Hs578T  MDA-MB-157  UACC-893  HCC-1428  HCC-1806  BT-474  MDA-MB-231  MDA-MB-453  MDA-MB-468  MDA-kB2  MDA-MB-415  HCC2157  MDA-MB-134-VI  HCC1569  HCC1599  HCC- MDA-MB-468 and HCC1569 cells. Live cell images showed nuclear localization of A3B-eGFP, in contrast to the cytoplasmic localization of an A3F-eGFP construct ( Fig. 1b and Supplementary Fig. 5 ). Corroborating data were obtained for haemagglutinin (HA)-tagged proteins ( Supplementary Fig. 5 ). To study endogenous A3B subcellular compartmentalization and activity, we used a fluorescence-based DNA C-to-U assay. We first found that nuclear, but not cytoplasmic, fractions of several breast cancer cell lines contain a robust DNA editing activity, which could be ablated by APOBEC3B knockdown (Fig. 1c and Supplementary Figs 6 and 7) . Similar results were obtained with an independent knockdown construct (not shown). Protein extracts were then used to assess the local dinucleotide deamination preference of endogenous A3B. Similar to retroviral hypermutation signatures caused by A3B overexpression 16 , endogenous A3B showed a strong preference for editing cytosines in the TC dinucleotide context ( Fig. 1d and Supplementary Fig. 6 ). No deaminase activity was observed for extracts from MCF-10A (A3B low ) or SK-BR-3 (A3B null ) cells, although it could be conferred by transient A3B transfection (Supplementary Fig. 8 ). Both A3B-HA and A3A-HA could elicit measurable TC-to-TU activity in lysates from transfected HEK293T cells ( Supplementary Fig. 9 ). However, because APOBEC3A mRNA is myeloid lineage-specific 17 and non-detectable in breast cancer cell lines (Supplementary Figs 1 and 2), our expression and activity studies indicated that A3B may be the only enzyme poised to deaminate breast cancer genomic DNA.
To address whether endogenous A3B damages genomic DNA, we used a combination of biophysical and genetic assays. We first used a mass spectrometry-based approach to quantify levels of genomic uracil in MDA-MB-453 and HCC1569 cells with high levels of endogenous A3B versus knockdown levels of A3B (short hairpin RNA (shRNA) control versus shRNA against APOBEC3B (shA3B)) ( Fig. 2a and Supplementary Fig. 10 ). Genomic uracil loads decreased by 30% in HCC1569 cells expressing shA3B and by 70% in MDA-MB-453 cells, in which knockdown was stronger ( Fig. 2b and Supplementary Fig. 10 ). Although these relative differences may seem modest-10 and 20 uracils per megabases (Mb), respectively-this equates to 30,000 and 60,000 A3B-dependent uracils per haploid genome. The actual number of pro-mutagenic uracils may be even higher because several repair pathways may concurrently function to limit this damage.
Second, we used a thymidine kinase-positive (TK plus ) to -negative (TK minus ) fluctuation analysis 17 to determine whether upregulated A3B and increased uracil loads lead to higher levels of mutation. MDA-MB-453 and HCC1569 cells were engineered to express the herpes simplex virus type 1 TK gene, which confers sensitivity to the drug ganciclovir. TK plus lines were transduced with shA3B or shControl constructs, and limiting dilution was used to generate single-cell subclones. Expanded subclones were subjected to ganciclovir selection and resistant cells were grown to visible colonies, which showed that cells with upregulated A3B accumulate 3-5-fold more mutations ( Fig. 2c and Supplementary Fig. 10 ).
Third, differential DNA denaturation PCR (3D-PCR) 17 ,18 was used to determine whether C-to-T transition mutations accumulate differentially at three genomic loci in A3B low and A3B high pools of HCC1569 cells. This technique enables qualitative estimates of genomic mutation within a population of cells because DNA sequences with higher A/T content amplify at lower denaturation temperatures than parental sequences. Lower temperature amplicons were observed for TP53 and c-MYC, but not CDKN2B (Fig. 2d and Supplementary Fig. 10 ). These amplicons were cloned and sequenced, and more C-to-T transition mutations were observed in A3B high compared with A3B low samples ( Fig. 2d and Supplementary  Fig. 10 ). TP53 and c-MYC appeared more mutable than CDKN2B, suggesting that all genomic regions are not equally susceptible to enzymatic deamination. Other base substitution mutations were rare, and some C-to-T transitions were still evident in the A3B low samples, possibly owing to residual deaminase activity and/or amplification of spontaneous events.
To address whether A3B triggers other cancer hallmarks 19 , we tried and failed to stably express A3B in several epithelial cell lines. We therefore constructed a panel of HEK293 clones with doxycycline (Dox)-inducible A3B, A3B(E68A/E255Q), A3A, or A3A(E72A) eGFP fusions. As measured by flow cytometry, A3-eGFP levels were barely detectable without Dox and induced in nearly 100% of cells with Dox ( Supplementary Fig. 11 ). A3A overexpression caused rapid S-phase arrest, cytotoxicity and c-H2AX focus formation, as reported previously 20 ( Fig. 3a-c and Supplementary Fig. 11 ). In comparison, A3B induction caused a delayed cell cycle arrest, a more pronounced formation of abnormal anucleate and multinucleate cells, and eventual cell death (Fig. 3a, b and Supplementary Fig. 11 ). A3B induction also caused c-H2AX focus formation, DNA fragmentation, as evidenced by visible comets, and C-to-T mutations (Fig. 3c-e) . A3B catalytic activity, as evidenced by the glutamate mutants, was required for the induction of these cancer phenotypes. Fig. 10 for further data.
LETTER RESEARCH
We next asked whether our cell-based results could be extended to primary tumours. First, we quantified mRNA levels for each of the 11 family members in 21 randomly chosen breast tumour specimens, in parallel with matched normal tissue procured simultaneously from an adjacent area or the contralateral breast. Only APOBEC3B was expressed preferentially in tumours (P 5 0.0003) (Supplementary Fig. 12 ). We confirmed this analysis by measuring APOBEC3B levels in 31 additional tumour/normal matched tissue sets. In total, APOBEC3B was upregulated by $3 s.d. in 20 out of 52 tumours in comparison to the patient-matched normal tissue mean, and in 44 out of 52 tumours in comparison to the reduction mammoplasty tissue mean ( Fig. 4a ; P 5 7.1 3 10 27 and P 5 2 3 10
25
, respectively; patient information in Supplementary Table 10 ). These are underestimates because tumour specimens have varying fractions of non-APOBEC3B-expressing normal cells. Some of the matched 'normal' samples may also be contaminated by tumour cells, as judged by the mean levels in mammoplasty samples ( Fig. 4a ; P 5 0.002). The related deaminase, APOBEC3G, was not expressed differentially in these samples, indicating that these observations are not due to immune cells known to express several APOBEC3 proteins 14 (P 5 0.591). Similar results were obtained by quantifying RNAsequencing data for independent matched tumour and normal pairs 21 , with ,50% showing upregulated A3B (defined as tumours with A3B levels .3 s.d. above the mean of the normal matched samples; P , 0.0001) (Fig. 4b) .
Finally, we assessed the effect of A3B on the breast tumour genome by correlating the deamination signature of A3B in vitro and the somatic mutation spectra accumulated during tumour development in vivo. Using a series of single-stranded DNA substrates varying only at the immediate 59 or 39 position relative to the target cytosine (underlined), we found that recombinant A3B prefers TC.CC. GC 5 AC and CA.CT 5 CC (Supplementary Fig. 13 ). These local sequence preferences were then compared to the expected distribution of cytosine in the human genome and the reported C-to-T mutation profiles for melanoma 22 , liver 23 and breast 8, 9, 21 tumours. Consistent with a spontaneous origin, the C-to-T frequency is low in liver tumours (,20%) and mutational events appear random (Fig. 4c,  d ). As expected, C-to-T frequencies are high in melanomas (,80%) and focused at dipyrimidines consistent with ultraviolet-induced lesions and subsequent error-prone lesion bypass synthesis (Fig. 4c,  d) . Interestingly, the C-to-T frequency was intermediate in three independent breast tumour data sets (,40%) and largely focused at trinucleotides that mimic the preferred sites for A3B-dependent DNA deamination in vitro (Fig. 4c, d and Supplementary Fig. 13 ). The availability of both high-throughput RNA sequencing (RNA-seq) and somatic mutation data 21 also enabled the establishment of strong positive correlations between APOBEC3B expression levels and the C-to-T mutation load, overall base substitution mutation load, and TP53 inactivation (Fig. 4e-g ). Importantly, tumours expressing high A3B levels have twice as many mutations (Fig. 4e, f and Supplementary  Fig. 14) . This equates to 10 C-to-T and 30 total mutations per exome, or approximately 1,000 and 3,000 mutations per genome, being attributable to A3B.
Taken together, we conclude that A3B is an important mutational source in breast cancer accounting for C-to-T mutation biases and increased mutational loads. Moreover, the disproportional increase in overall base substitutions indicates that some of these other patterns may be due to further processing of U/G mispairs by 'repair' enzymes into transitions, transversions and DNA breaks that could precipitate chromosomal rearrangements (model in Supplementary Fig. 15 with similarities to AID-dependent antibody diversification mechanisms 24 ). Future work is needed to understand A3B regulation and the potential interaction with other oncogenes and tumour suppressors. For example, although several common breast cancer markers do not correlate with APOBEC3B upregulation, a mechanistic linkage between increased APOBEC3B and inactivated TP53 is evident in primary tumour data and cell lines ( Fig. 4g and Supplementary Fig. 16 ). TP53 inactivation may be required to allow cells to bypass DNA damage checkpoints triggered by A3B. This is the first study, to our knowledge, to demonstrate upregulation of the DNA deaminase A3B in breast cancer and reveal it as a considerable source of enzymatic mutation. Conceptually supportive of the original mutator hypothesis 25 , A3B-catalysed genomic DNA deamination could provide genetic fuel for cancer development, metastasis, and even therapy resistance. We propose that A3B is a dominant underlying factor that contributes to tumour heterogeneity by broadly affecting several pathways and phenotypes. A3B may represent a new marker for breast cancer and a strong candidate for targeted intervention, especially given its non-essential nature 26 . A3B inhibition may decrease the rate of tumour evolution and stabilize the targets of existing therapeutics. P-0085 P-0561 P-0937 P-1115 P-0560 P-0158 P-0238 P-0604 P-0627 P-0828 P-0932 P-0594 P-1425 P-0987 P-3046 P-0641 P-0251 P-0304 P-1214 P-0060 P-0007 P-0294 P-0125 P-1862 P-0858 P-0277 P-1113 P-7142 P-2248 P-2100 P-2250 P-0480 P-2296 P-9407 P-2498 P-1827 P-2671 P-7020 P-2388 P-1552 P-1792 P-1969 P-0637 P-1127 P-1624 P-2659 P-1674 P-2083 P-1656 P-8887 P-1677 P-1121 P-2528 P-1360 P-1734 P-1651 P-2009 P-1460 P-0121 P-1367 P-8277 P-9378 P-1684 P-1094 P-1017 P-6841 P-0385 P-1441 P-0504 P-0656 P-8364 P-7671 P-9170 P-2625 P-1257 P-1150 P-9773 P-9169 P-9863 A0AU  A158  A1ET  A2C8  A15I  A0E0  A1NG  A0DO  A1RC  A1FH  A153  A0D9  A0BT  A1EU  A18N  A1RD  A0DT  A208  A0AZ  A18M  A0BM  A18S  A209  A1RI  A1R7  A1FG  A1NF  A0DV  A0BQ  A1IG  A1EO  A0AY  A1FN  A13G  A1LS  A18K  A0BV  A1FR  A0BA  A1EN  A0DB  A0C3  A1RB  A0DP  A1NA  A0DD  A15M  A204  A0H5  A1F8  A0DQ  A1FD  A1L7  A0BS  A1EW  A0HA  A13F  A1EV  A0BZ  A0B7  A1N4  A0BJ  A1FE  A18L  A1N5  A1N9  A1ND  A18Q  A0DL  A0HK  A1FM  A0H7  A18P  A0DG  A1RF  A0E1  A1FJ  A1FU  A0B5  A1LB  A0DH  A0BC  A1F2  A18R  A0B3  A0C0  A0DK  A1FC  A0B8  A18U  A1F0  A1RH  A1F6  A0BW  A203  A18V Table 11 ). Knockdown and control shRNA constructs were obtained from Open Biosystems. Microscopy, cellular fractionation and deaminase activity assays were done as described 15, 17 . Genomic uracil was quantified by treating DNA samples with uracil DNA glycosylase, purifying the nucleobase away from the remaining DNA, and analysing the samples by mass spectrometry. The TK and 3D-PCR mutation assays have been described and were modified for use with breast cancer cell lines 17 . Dox-inducible cells were obtained from Invitrogen and stable derivatives were created with the indicated constructs. These lines were analysed for cell cycle arrest using propidium iodide staining and cell viability with crystal violet staining and the MTS assay. DNA damage was measured by the comet assay and by flow cytometry and microscopy of cells immunostained for c-H2AX. Recombinant A3B195-382-mycHis was purified and used for deamination kinetics as described 27 using 59-ATTATTATTATNCNAATGGATTTATTTATTTATTTATTTATTT-6-FAM (NCA and TCN for 59 and 39 preference experiments, respectively). The somatic single-nucleotide mutation frequencies with local sequence contexts were determined by compiling published primary tumour genomic, exomic or RNA sequencing data 8, 9, [21] [22] [23] . Potential mechanistic overlap with hydrolytic deamination of 5-methyl-cytosines was avoided by excluding CpG dinucleotides from mutational preference calculations.
Full Methods and any associated references are available in the online version of the paper.
